Hansa Biopharma

#Transplantation #Complement-mediated Diseases #Autoimmune

Swedish biopharma developing enzyme therapies for kidney transplantation and complement-mediated diseases. Lead product Idefirix for desensitization in kidney transplant.

Company Info

Sector:Biologics

Headquarters:Lund, Sweden

Founded:2007

Website:www.hansabiopharma.com/

Upcoming Milestones & Key Dates

2026-Q4

Regulatory

FDA verdict on Idefirix US filing

2027-Q1

Clinical

Anti-GBM Phase 2 data readout

Clinical Development Pipeline

Idefirix (imlifidase)

Target: IgG antibody cleavage

Desensitization in kidney transplant

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Idefirix

Target: IgG antibody cleavage

Anti-GBM disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

HNSA-5471

Target: IgG cleavage

IgG-mediated autoimmune disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Renée Aguiar-Lucander

CEO

Evan Ballantyne

CFO

Christian Kjellman

COO

Careers & Job Openings

See all open roles

Various

Lund, Sweden

Apply Now →